JPRN-UMIN000006286已完成2 期
Randomized study of tamoxifen versus goserelin acetate vs combination as preoperative endocrine therapy for estrogen receptor positive pre-menopausal patients. - Randomized study of tamoxifen versus goserelin acetate versus combination as preoperative endocrine therapy.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 30years-old 至 55years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) hypersensitivity to test drug 2) serious complication (malignant hypertention, congestive heart failure, coronary failure, cardiac infarction in last 6 month, arhythmia which need treatment, infection disease, bleeding tendency, etc.) 3) Patients who administrate anticlotting drug or SSRI 4)Patinent who have double cancer 5)Ductal carcinoma in situ or inflamatory breast cancer 6) Bilateral breast cancer, male breast cancer 7) Pregnant women, breat-feeding mother, possibility of pregnancy 8) History of thrombosis 9) History of mental disease or under medical treatment. 10)Patient regarded as inadequate by responsible doctor
研究者
相似试验
进行中（未招募）
不适用
A Randomized Trial of Temsirolimus and Sorafenib as Second-Line Therapy in PatientsWith Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib TherapyPatients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib TherapyEUCTR2007-000062-20-NLWyeth Research Division of Wyeth Pharmaceuticals Inc. Global Medical Affairs440
进行中（未招募）
不适用
A Randomized Trial of Temsirolimus and Sorafenib as Second-Line Therapy in PatientsWith Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib TherapyEUCTR2007-000062-20-DEWyeth Research Division of Wyeth Pharmaceuticals Inc. (A Pfizer Company)480
进行中（未招募）
1 期
A Randomized Trial of Temsirolimus and Sorafenib as Second-Line Therapy in PatientsWith Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib TherapyEUCTR2007-000062-20-FRWyeth Research Division of Wyeth Pharmaceuticals Inc. Global Medical Affairs440
进行中（未招募）
不适用
A Randomized Trial of Temsirolimus and Sorafenib as Second-Line Therapy in Patients with Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy - NDEUCTR2007-000062-20-ITWyeth Research Division of Wyeth Pharmaceuticals Inc Global Medical Affairs440
进行中（未招募）
1 期
Ensayo aleatorizado de temsirolimus y sorafenib como tratamiento de segunda línea en pacientes con carcinoma de células renales avanzado tras el fracaso del tratamiento de primera línea con sunitinibA Randomized Trial of Temsirolimus and Sorafenib as Second-Line Therapy in PatientsWith Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib TherapyEUCTR2007-000062-20-ESWyeth Research Division of Wyeth Pharmaceuticals Inc. Global Medical Affairs440